Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Modafinil and fatigue in multiple sclerosis].

N Téllez1, X Montalbán

  • 1Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona. ntellez@vhebron.net

Neurologia (Barcelona, Spain)
|October 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic MRI in Progressive MS: Associations with Disability.

AJNR. American journal of neuroradiology·2025
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

[Nicolau syndrome due to self-injectable drugs in multiple sclerosis].

Revista de neurologia·2023
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

Revista de neurologia·2023
Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)].

Revista de neurologia·2023
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Modafinil shows promise for treating fatigue in multiple sclerosis (MS) patients. This drug, a wakefulness promoter, offers potential efficacy and safety, encouraging further research into its use for MS-related fatigue.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • Fatigue is a prevalent and debilitating symptom in multiple sclerosis (MS).
  • The exact causes of MS fatigue are complex and multifactorial, making treatment challenging.
  • Current treatments for MS fatigue have shown limited efficacy and short-term benefits.

Purpose of the Study:

  • To evaluate modafinil as a potential treatment for fatigue in patients with multiple sclerosis.
  • To assess the efficacy and safety of modafinil for managing MS-related fatigue.

Main Methods:

  • Review of existing studies on modafinil for MS fatigue.
  • Analysis of modafinil's proposed mechanism of action, including its effects on brain waves and vigilance.
  • Consideration of modafinil's safety profile in the context of MS treatment.

Related Experiment Videos

Main Results:

  • Preliminary studies suggest modafinil may be an effective treatment for MS fatigue.
  • Modafinil is a wakefulness-promoting agent with a distinct mechanism of action compared to other stimulants.
  • Modafinil increases high-frequency alpha waves and reduces delta and theta waves, enhancing vigilance.

Conclusions:

  • Modafinil presents a promising therapeutic option for managing fatigue in multiple sclerosis patients.
  • The observed efficacy and safety profile of modafinil warrant further investigation in this patient population.
  • Continued research is encouraged to solidify modafinil's role in treating MS-related fatigue.